ABSTRACT
Chronic pain is a significant problem that afflicts individuals and society, and for which the current clinical treatment is inadequate. In addition, the neural circuit and molecular mechanisms subserving chronic pain remain largely uncharacterized. Herein we identified enhanced activity of a glutamatergic neuronal circuit that encompasses projections from the ventral posterolateral nucleus (VPLGlu) to the glutamatergic neurons of the hindlimb primary somatosensory cortex (S1HLGlu), driving allodynia in mouse models of chronic pain. Optogenetic inhibition of this VPLGlu→S1HLGlu circuit reversed allodynia, whereas the enhancement of its activity provoked hyperalgesia in control mice. In addition, we found that the expression and function of the HCN2 (hyperpolarization-activated cyclic nucleotide-gated channel 2) were increased in VPLGlu neurons under conditions of chronic pain. Using in vivo calcium imaging, we demonstrated that downregulation of HCN2 channels in the VPLGlu neurons abrogated the rise in S1HLGlu neuronal activity while alleviating allodynia in mice with chronic pain. With these data, we propose that dysfunction in HCN2 channels in the VPLGlu→S1HLGlu thalamocortical circuit and their upregulation occupy essential roles in the development of chronic pain.
Keywords: chronic pain, HCN2 channels, neural circuit, in vivo recordings
The pain hypersensitivity is linked to functional connections between the thalamus and the cortical regions and we identified that the regulation of HCN2 channel encode the excitability of the VPLGlu→S1HLGlu thalamocortical circuit which promotes the development of chronic pain.
INTRODUCTION
Chronic pain is a pervasive, complex global health problem that is one of the principal causes of disease burden and disability [1]. Many analgesic drugs used in the treatment of chronic pain, including opioids and non-steroidal anti-inflammatory drugs (NSAIDs), are presently used for pain management during or after surgery [2]. However, side effects such as respiratory depression, nausea and vomiting, itching of the skin, and drug addiction due to long-term abuse continue to be problematic for both doctors and patients. Hence, it is essential to uncover innovative therapies for the treatment of chronic pain.
Nociceptive stimuli caused by tissue injury are transmitted to the central nervous system (CNS) via multiple pain-ascending pathways from the spinal cord [3]; and many brain regions such as the thalamus, primary somatosensory cortex (S1) [4,5], anterior cingulate cortex (ACC) [6–8], and insular cortex (IC) [9] are involved in the central regulation of chronic pain. Of these, the thalamus is the relay station for receiving information from multiple ascending pathways and transmitting nociceptive information to multiple cortices [10]. The ventral posterolateral nucleus (VPL) is known to be the principal somatosensory nucleus of the thalamus and the VPL processes and integrates pain information while distinguishing sensory and emotional dimensions [11]. Studies in animals have shown that inhibiting extracellular glutamate release in the VPL attenuates mechanical allodynia in a mouse model of spared nerve injury (SNI) [12]. In addition, clinical studies have also revealed that targeted excitation of the VPL nucleus by deep-brain stimulation can be used to treat a variety of pain syndromes [13]. The cortex receives information integrated by the thalamus for pain processing [8], and thalamocortical arrhythmias comprise one of the key pathological mechanisms governing chronic pain [14]. Use of functional magnetic resonance imaging (fMRI) found that enhanced connections between the VPL and somatosensory cortex in patients with chronic back pain [15], and the accurate inhibition of these functional connections produced a reduction in clinical pain by transcranial direct-current stimulation [16]. Collectively, these studies indicate that the VPL and its related thalamocortical circuit connections are associated with nociceptive processing. However, the molecular mechanisms subserving the VPL-related neuronal circuits in the pathogenesis of chronic pain are still largely undetermined.
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are voltage-gated cation channels that are composed of four isoforms (HCN1–4) [17]. Since HCN channels were first reported to regulate the rhythm of myocardial sinoatrial nodal cells [18], HCN channels have subsequently been identified as widely expressed in the central and peripheral nervous systems; they appear to be critical to a series of physiological processes and pathological diseases—including pain [19], depression [20], epilepsy [21], and learning and memory [22]. Regarding the role of HCN channels in the occurrence and information transmission of pain [23], recent studies have revealed that mice with a genetic deletion of HCN2 channels showed the elimination of action potential firing in small dorsal root ganglion (DRG) neurons [24]. In addition, the expression of HCN2 channels in DRG neurons was enhanced in a mouse model of chronic pain [25]. These findings provide strong evidence that HCN2 channels may constitute an analgesic target in the treatment of chronic pain. Although HCN2 channels are widely expressed in the thalamus [17], the mechanism(s) by which they regulate the activity of thalamocortical circuits in chronic pain remains largely unelucidated.
In the present study, we demonstrated that the upregulation of HCN2 channels promoted augmented excitability of glutamatergic neurons of the VPL (VPLGlu) in mouse models of chronic pain and that this effect resulted in hyperactivity of the glutamatergic neurons of the hindlimb primary somatosensory cortex (S1HLGlu). Our findings thus suggest that upregulation of HCN2 channels is essential in the development of chronic pain, and that blocking their activity in VPLGlu neurons comprises a feasible approach for the development of a novel class of analgesic drugs.
RESULTS
Enhanced VPLGlu neuronal activity in mouse models of chronic pain
We established the spared nerve injury (SNI)-induced neuropathic pain model (Fig. 1a) and the complete Freund's adjuvant (CFA)-induced inflammatory pain model in mice (Fig. S1a), which are two well-known mouse models of chronic pain [26]. Seven days after SNI (SNI 7D) or three days after CFA injection (CFA 3D), the mice displayed a significant reduction in their mechanical threshold to allodynia by von Frey tests (Fig. 1b, Fig. S1b).
The VPL is classically described as a major relay station for pain-signal transmission that integrates pain-related information from regions such as the spinal cord and brainstem [27]. We therefore investigated neuronal activity in the VPL by observation of the expression of c-Fos, an immediate-early gene marker, and observed that c-Fos–positive neurons in the VPL were markedly elevated in SNI 7D mice and CFA 3D mice compared with control mice (Fig. 1c, Fig. S1c). Subsequent immunofluorescence staining showed that ∼90% of c-Fos signal was co-labeled with the glutamate antibody, which has been widely employed to identify cortical and subcortical glutamatergic neurons in other previous studies [28–30], in the VPL of both SNI 7D mice and CFA 3D mice (Fig. 1d, Fig. S1d). To validate the specificity of anti-Glu antibody, we injected a VGluT2 promoter virus (AAV-VGLUT2-EGFP) and a CaMKII promoter virus (AAV-CaMKII-mCherry) into the VPL of C57 mice (Fig. S2a). After three weeks, immunofluorescence staining showed that mCherry-positive neurons were co-labeled with EGFP-positive neurons (Fig. S2b and c); the co-labeled neurons also co-localized with immunofluorescence signal of the glutamate antibody (Fig. S2d and e).
To examine the neuronal excitability of VPLGlu neurons, we executed whole-cell patch-clamp electrophysiological recordings of red fluorescent protein tdTomato-expressing VPLGlu neurons in brain slices from CaMKII-Ai14 mice produced by Ca2+/calmodulin-dependent protein kinase II-Cre mice crossed with Ai14 mice (Fig. 1e). We observed an increase in firing rate and a decrease in rheobase of current-evoked action potentials (tonic firing) (Fig. 1f–h), accompanied by a depolarized resting membrane potential (RMP) and no change in input resistance (Rin) (Fig. 1i and j) in SNI 7D mice compared to that in sham mice. In addition, to further directly explore the role of VPLGlu neuronal activity in freely moving mice, in vivo multi-channel electrode recordings were performed (Fig. 1k). We first identified the characteristics of spike waveforms by laser stimulation (473 nm, 20 Hz, 15 ms) of VPLGlu neurons with VPL infusion of an adeno-associated virus (AAV) expressing Cre-dependent channelrhodopsin-2 (AAV-DIO-ChR2-mCherry) in the CaMKII-Cre mice (Fig. S3) under in vivo multi-channel optrode recordings, and we found that the spontaneous spike firing rate of VPLGlu neurons was augmented in SNI 7D mice compared with that in sham mice (Fig. 1l and m). Moreover, to determine whether the activity of VPLGlu neurons was sensitized to subthreshold stimuli, we measured Ca2+ signals in VPLGlu neurons using the optical fiber photometer recordings of C57 mice harboring the virally expressed fluorescent Ca2+ indicator GCaMP6m (AAV-CaMKII-GCaMP6m) (Fig. 1n and o) and demonstrated that Ca2+ signals in VPLGlu neurons increased rapidly following 0.07-g von Frey stimuli on the injured paws of SNI 7D mice (Fig. 1p and q). This suggested that VPLGlu neurons became sensitized and activated more readily, which may have caused the increased spontaneous firing of VPLGlu neurons during chronic pain.
Similarly, in CFA 3D mice, we also uncovered an elevation in current-evoked action potentials and a depolarized RMP with no change in Rin compared to saline mice (Fig. S4a–e). In addition, the enhanced activity of VPLGlu neurons were also obtained in CFA 3D mice using in vivo multi-channel electrode and optical fiber photometry recordings (Fig. S4f–i). Collectively, these data suggested that VPLGlu neuronal activity was enhanced under conditions of chronic pain.
Manipulation of VPLGlu neuronal activity regulates pain sensitization in mice
To further probe how VPLGlu neurons participated in pain sensitization, we employed a chemogenetic inhibitory hM4Di virus (AAV-CaMKII-hM4Di-mCherry) under the regulation of a CaMKII promoter and the intraperitoneal injection of its ligand clozapine-N-oxide (CNO) to selectively inhibit VPLGlu neurons in SNI 7D mice (Fig. 2a and b). Electrophysiological recordings from brain slices (Fig. 2c) revealed that the RMP of the hM4Di-mCherry+ VPLGlu neurons was significantly hyperpolarized after perfusion of CNO (10 μM) (Fig. 2d), indicating that the chemogenetic virus was successfully expressed in VPLGlu neurons. Under in vivo multi-channel electrode recordings, we also showed that chemogenetic inhibition of VPLGlu neurons significantly reversed the SNI-induced enhancement of spontaneous firing (Fig. 2e and f), and prevented the SNI-induced allodynia that was manifested as a recovery of the mechanical pain threshold using von Frey tests (Fig. 2g) in SNI 7D mice. We additionally noted similar results in CFA 3D mice (Fig. S5).
We also infused an optogenetically stimulated, ChR2-expressing virus (AAV-CaMKII-ChR2-mCherry) into the VPL of C57 mice (Fig. 2h and i), and found that pulsed blue-light stimulations evoked action potentials in ChR2-mCherry+ VPLGlu neurons (Fig. 2j and k) that led to a reduction in the threshold of mechanical pain in normal mice (Fig. 2l). These results confirmed the functional causality of the VPLGlu neurons in mechanical allodynia of our mouse models of chronic pain.
Upregulation of HCN2 channels enhances VPLGlu neuronal activity in mouse models of chronic pain
We next investigated the molecular mechanisms underlying the elevation in VPLGlu neuronal activity in mouse models of chronic pain. By delivering a series of hyperpolarized currents (from −10 pA to −300 pA, −10 pA/step, 500 ms) into VPLGlu neurons (Fig. 3a), we found that the number of action potentials in the burst that appeared at the termination of pulses significantly increased, and that the rheobase of the burst firing diminished (Fig. 3b and c). Interestingly, the amplitude of a rebound depolarization (i.e., sag) at hyperpolarized potentials, measured as the difference between the peak membrane potential of the hyperpolarization (Vpeak) and the steady-state potential (Vss) near the end of the current steps, was larger in SNI 7D mice than in sham mice (Fig. 3d). The sag amplitude is a characteristic voltage change that indicates activation of the Ih current as mediated by HCN channels [31], and HCN channels are known to play a key role in controlling neuronal excitability and participate in pain sensitization [32].
There are four isoforms of HCN channels (HCN1–4) that are expressed in the CNS [31]. Using immunofluorescent staining, we found that HCN2, HCN3 and HCN4 were distributed in the VPL (Fig. S6). In addition, Western blots showed that protein levels of HCN2 in the VPL were upregulated in SNI 7D mice and CFA 3D mice (Fig. 3e, Fig. S7a), while no change in HCN4 protein level was observed in this group of mice, as compared to their respective controls (Fig. 3g, Fig. S7c). Moreover, no change in HCN3 protein levels was detected in SNI 7D mice compared to sham mice (Fig. 3f), and only a slight increase was detected in CFA 3D mice compared to saline mice (Fig. S7b). These results suggested that although HCN2, HCN3 and HCN4 channels are all distributed in the VPL, only HCN2 expression is significantly upregulated in both SNI and CFA mouse models.
Further immunofluorescent staining showed that HCN2 channels were highly expressed in VPLGlu neurons in mice (Fig. S8a). To better understand the contribution of HCN2 channels in the VPLGlu neurons to chronic pain, we then used electrophysiological recordings in whole-cell voltage-clamp mode as described previously [31] to specifically isolate HCN2 channel-mediated–Ih currents by holding membrane voltage at −50 mV with 5 s-long voltage steps from −50 mV to −130 mV (Fig. 3h), and these currents could be eliminated by bath application of the HCN channel-specific blocker ZD7288 (10 μM) (Fig. S8b and c). We found that the Ih current density was higher in the VPLGlu neurons of SNI 7D mice compared to that of sham mice (Fig. 3i), indicating that HCN2 channel function was enhanced in SNI 7D mice. The function of HCN2 in cells is to enhance neuronal activity [33], and the enhanced Ih currents may, therefore, result in hyperactive tonic and burst firing of the VPLGlu neurons in mice with chronic pain.
Next, we additionally examined whether blocking HCN2 channels exerted any effects on VPLGlu neuronal activity and allodynia of SNI 7D mice (Fig. 3j and k). Using in vitro electrophysiological recordings in brain slices, we found that the number of current-evoked tonic spikes decreased while the rheobase of the spike increased (Fig. 3l–n); this was accompanied by decreased burst firings and sag amplitude, increased rheobase of burst spike, hyperpolarized RMP, and raised Rin (Fig. 3o–t) in VPLGlu neurons of SNI 7D mice with ZD7288 microinjected intracranially into the VPL compared to SNI 7D mice with artificial cerebrospinal fluid (ACSF) treatment. In addition, behavioral tests showed the allodynia was relieved in SNI 7D mice after being treated with ZD7288 compared to those mice treated with ACSF (Fig. 3u). Similar results were observed in CFA 3D mice (Fig. S9). Taken together, these data suggested that the functional upregulation of the HCN2 channels may comprise one of the molecular mechanisms subserving allodynia in chronic pain conditions.
Elucidation of an excitatory VPLGlu→S1HLGlu pathway
The most distinctive feature of the thalamus is its ability to transfer pain signals to the cerebral cortex for the integration and differentiation of pain [34]. To dissect the functional connection of this distinct pathway between the VPL and cortex, the AAV-CaMKII-ChR2-mCherry virus was infused into the VPL of C57 mice (Fig. 4a–c). Three weeks later, strong mCherry+ fibers were observed in the S1HL (Fig. 4d) that is known to mediate the sensory-discriminative aspects of hindlimb nociception [35], and not in the ACC, IC, or prefrontal cortex (PFC) (Fig. S10a and b). To confirm this VPL→S1HL projection, we injected anterograde monosynaptic AAV-Cre-GFP virus into the VPL and AAV-DIO-GFP virus into the S1HL of C57 mice (Fig. 4e and f). Three weeks later, we observed neurons with a positive green fluorescent protein (GFP+) in the S1HL (Fig. 4g) that was predominantly co-localized with the glutamate antibody (Fig. 4h and i).
To further scrutinize VPL→S1HL organization, we used a cell-type–specific retrograde trans-monosynaptic tracing system. Cre-dependent helper viruses (AAV-EF1α-DIO-TVA–GFP and AAV-EF1α-DIO–RVG) were injected into the S1HL of CaMKII-Cre mice (Fig. 4j, Fig. S10c), and after three weeks rabies virus (RV) (EnvA-pseudotyped RV-ΔG-DsRed) was injected into the same site (Fig. 4k); the presence of these helper viruses enabled the rabies virus to retrograde across monosynapses. We observed obvious DsRed-labeled neurons in the VPL, the posterior thalamic nucleus (PO), the zona incerta (ZI), contralateral S1HL, and the secondary somatosensory cortex (S2) (Fig. 4l, Fig. S10d and e); we noted that this signal was co-labeled with the glutamate antibody signal (Fig. 4m). Intriguingly, the DsRed-labeled neurons in the VPL were co-labeled with glutamate and HCN2 antibodies (Fig. S10f). These findings demonstrated a VPLGlu→S1HLGlu thalamocortical pathway.
To characterize the functional connections of the VPLGlu→S1HLGlu pathway, optogenetic experiments were performed by injection of AAV-DIO-ChR2-mCherry into the VPL and AAV-DIO-EYFP into the S1HL (Fig. 4n). Whole-cell recordings in brain slices showed that brief light stimulation of ChR2-containing VPLGlu terminals in the S1HL reliably elicited excitatory postsynaptic currents (EPSCs) in the S1HLGlu neurons. These EPSCs were blocked by bath application of the brain slices with tetrodotoxin (TTX, 1 μM), and the blockage was rescued by the addition of the potassium-channel blocker 4-aminopyridine (4-AP, 4 mM) to the TTX treatment. This rescue effect could then be eliminated by adding the AMPA receptor antagonist 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (DNQX, 20 μM) to the TTX/4-AP co-treatment (Fig. 4o and p). These results demonstrated that S1HLGlu neurons received functional monosynaptic excitatory glutamatergic projections from VPLGlu neurons.
Functional role of the VPLGlu→S1HLGlu pathway in mouse models of chronic pain
To further detect whether the VPLGlu→S1HLGlu pathway is overexcited under chronic pain conditions, we investigated the synaptic transmission of the VPLGlu→S1HLGlu pathway through VPL injection with AAV-DIO-ChR2-mCherry and S1HL injection with AAV-DIO-EYFP in CaMKII-Cre mice (Fig. 5a). With a holding potential of −70 mV, we recorded the light-evoked EPSCs of EYFP+ S1HLGlu neurons induced by photostimulating (473 nm, pulse width 10 ms, 50 ms interstimulus interval) ChR2+ VPLGlu terminals in the S1HL in brain slices (Fig. 5b). The paired-pulse ratios of light-evoked EPSCs (PPR, ratio of EPSC2 over EPSC1) were decreased in S1HLGlu neurons of SNI 7D compared to that in control mice (Fig. 5b and c). These results suggested increased presynaptic glutamate release from VPLGlu neurons to S1HLGlu neurons in the current models of chronic pain.
In light of our findings, we hypothesized that if S1HL neurons were innervated by VPLGlu inputs in an excitatory state, then an increase in inputs under chronic-pain conditions should cause excitatory effects. To directly explore the role of S1HLGlu neuronal activity in freely moving mice, in vivo multi-channel electrode recordings were executed in both chronic pain and control mice. We first identified the characteristics of spike waveforms by laser stimulation (473 nm, 20 Hz, 15 ms) of S1HLGlu neurons with S1HL infusion of AAV-DIO-ChR2-mCherry virus in the CaMKII-Cre mice under in vivo multi-channel electrode recordings (Fig. S11), and found an increase in the firing rate of spontaneous spikes from S1HLGlu neurons in SNI 7D mice compared with sham mice (Fig. 5d and e). Similar results were obtained in photometric calcium-signal recordings (Fig. 5f), which showed that the Ca2+ signals in S1HLGlu neurons were increased after 0.07-g von Frey filament stimuli to the injured paws of SNI 7D mice (Fig. 5g and h, Video S1). To visualize Ca2+ signals in conscious mice, we injected the AAV-CaMKII-GCaMP6f-GFP virus into the S1HL (Fig. 5i), and in vivo two-photon calcium imaging showed that the fluorescence intensity and event of Ca2+ signals significantly increased in GCaMP6f-labeled S1HLGlu neurons in SNI 7D mice (Fig. 5j–l). Analogous to the results with SNI 7D mice, we also observed decreased PPR of light-evoked EPSCs (Fig. S12a–c) and enhanced activity of S1HLGlu neurons in CFA 3D mice (Fig. S12d–p). These results indicated that S1HLGlu neuronal excitability was enhanced by increases in the excitatory inputs received from VPLGlu neurons under conditions of chronic pain.
In order to evaluate the effects of manipulations of this neuronal circuit on S1HLGlu neuronal activity and pain behaviors, we found that the enhanced activity of S1HLGlu neurons was abolished by chemogenetic inhibition of VPLGlu neurons, which was manifested as a recovery of c-Fos expression (Fig. S13a–c), the spontaneous firing of S1HLGlu neurons using in vivo multi-channel electrode recordings and whole-cell recordings in brain slices in SNI 7D mice (Fig. 5m–r). In addition, the allodynia in SNI 7D mice was reversed by optical inhibition of VPLGlu terminals in the S1HL following VPL injection of AAV-CaMKII-eNpHR-EYFP virus (Fig. 5s–v). Similar reversed effects were also observed in CFA 3D mice (Fig. S13d–j). Furthermore, we also found that optical activation of VPLGlu fibers in the S1HL that expressed AAV-CaMKII-ChR2-mCherry virus induced allodynia in normal mice (Fig. S14). Taken together, our results revealed the functional causality in the VPLGlu→S1HLGlu pathway in the development of chronic pain.
Manipulation of HCN2 channels in VPLGlu neurons affects pain behaviors
Based on our evidence that HCN2 channels were functionally enhanced in VPLGlu neurons in mouse models of chronic pain, we hypothesized that the HCN2 channel was a potential analgesic target and investigated the role of HCN2 channels in regulating VPLGlu→S1HLGlu circuit activity in pain perception. Immunohistochemistry (Fig. 6a–d) and whole-cell recordings (Fig. 6e–h) in brain slices showed that the respective increases in both c-Fos expression and neuronal activity were abrogated in S1HLGlu neurons due to inhibition of HCN2 channels after intracranial microinjection of ZD7288 into the VPL of SNI 7D mice. To specifically block HCN2 channels in VPLGlu neurons, we used an RNA interference (RNAi) viral vector (AAV-DIO-mCherry-shRNA (HCN2)) to knockdown VPLGlu neuronal HCN2 protein levels and an AAV-DIO-mCherry-shRNA (scramble) as a control virus in CaMKII-Cre mice (Fig. 6i). Three weeks after the VPL injection of HCN2 RNAi virus (AAV-shRNA) (Fig. S15), immunofluorescence staining showed that ∼90% of mCherry+ neurons were co-localized with glutamate antibody in the VPL (Fig. 6j–l) and that VPLGlu neuronal HCN2 protein level was reduced to ∼52.8% of that in the AAV control group (AAV-mCherry) (Fig. 6m).
Behavioral testing was performed to examine the blockade effects of HCN2 channels in chronic-pain mice, and we noted that, compared with the AAV-mCherry group, HCN2 knockdown markedly reversed the reduction in the mechanical pain threshold in SNI 7D mice (Fig. 6n and o). In addition, optical-fiber photometer recordings revealed that the Ca2+ signals remained unchanged following stimuli of a 0.07-g von Frey filament to the injured hindpaws of SNI 7D mice with HCN2 channel knockdown in the VPL (Fig. 6p–r, Video S2). To further corroborate the effect on pain sensitization by specific knockdown of the HCN2 channels in the VPLGlu neurons projecting to the S1HL, we infused AAV-DIO-mCherry-shRNA (HCN2) virus into the VPL and retro-AAV-hSyn-Cre-EGFP into the S1HL (Fig. 6s and t) in C57 mice and found that the allodynia in these SNI 7D mice was still reversed (Fig. 6u). Similar results were obtained from CFA 3D mice (Fig. S16). Our collective findings from these disparate experimental manipulations suggested that the downregulation of HCN2 function in VPLGlu neurons sufficiently and effectively rescued the enhancement of VPLGlu→S1HLGlu circuit activity and allodynia in mouse models of chronic pain.
To further determine the effects of upregulation of HCN2 in the VPL→S1HL circuit on pain behaviors, we overexpressed the HCN2 protein in VPLGlu neurons by injecting an AAV-DIO-HCN2-3xflag virus (AAV-HCN2) or an AAV-DIO-3xflag virus (AAV-control) into the VPL of CaMKII-Cre mice (Fig. S17a). After three weeks, we found that ∼90% of mCherry+ neurons co-localized with glutamate antibody in the VPL (Fig. S17b–d). Western blots of VPL tissues showed that HCN2 protein levels in the AAV-HCN2 group were increased to ∼159% of that in the AAV-control group (Fig. S17e). In addition, electrophysiological recordings showed that Ih current density and neuronal activity were increased in AAV-HCN2–expressing VPLGlu neurons compared to those in VPLGlu neurons expressing AAV-control (Fig. S17f–p). Post hoc immunostaining showed that the recorded neurons in the VPL labeled with neuronbiotin-488 in pipette solution were glutamatergic (Fig. S17q). Moreover, optical-fiber photometer recordings revealed that the Ca2+ signals of S1HLGlu neurons were increased under HCN2 overexpression in VPLGlu neurons, compared with AAV-control mice (Fig. S17r–t, Video S3).
Behavioral tests showed that the mechanical pain threshold was lower in mice with HCN2 overexpression in VPLGlu neurons compared to that of AAV-control mice (Fig. S17u and v). Optogenetic inhibition of VPLGlu terminal activity in the S1HL reversed pain sensitization in AAV-HCN2 mice with VPL infusion of AAV-DIO-eNpHR3.0-EYFP virus (Fig. S17w–y). These data suggested that upregulation of HCN2 function in the VPLGlu→S1HLGlu pathway can generate pain behaviors.
The cAMP signaling mediates HCN2 channel activity in VPLGlu neurons in mouse models of chronic pain
HCN2 is regulated by membrane voltage and by intracellular cyclic adenosine monophosphate (cAMP) signaling. We exploited enzyme-linked immunosorbent assay of the cAMP and found that cAMP levels were significantly increased in the VPL of both SNI 7D and CFA 3D mice compared with that in the respective controls (Fig. S18a, Fig. S19a).
To understand the molecular mechanisms through which cAMP signaling may contribute to the HCN2-induced increase in VPLGlu neuronal activity, the cAMP inhibitor, SQ22536, was intracranially microinfused into the VPL (Fig. S18b, Fig. S19b). Whole-cell recordings showed that Ih current density and neuronal activity were significantly decreased in VPLGlu neurons of SQ22536-treated SNI 7D and CFA 3D mice compared with corresponding model mice treated with ACSF (Fig. S18c–m, Fig. S19c–m). Behavioral tests showed that SQ22536 application to the VPL significantly reduced mechanical pain thresholds in both SNI 7D and CFA 3D mice compared to model mice given ACSF (Fig. S18n, Fig. S19n). These results suggested that increased cAMP signaling can generate pain behaviors through HCN2 in mice with chronic pain.
DISCUSSION
This study reveals that HCN2 channels perform an essential function in the molecular basis underlying chronic pain by regulating thalamocortical circuit activity. Central to this process is the upregulation of HCN2 channel activity that leads to increased excitability of VPLGlu neurons; this is manifested as enhanced tonic and burst spikes, and results in the hyperactivity of S1HLGlu neurons under chronic-pain conditions (Fig. S20).
The mechanistic understanding of molecular underpinnings and functional regulation of VPLGlu neurons in pain remains largely elusive. Previous studies demonstrate that VPL neurons exhibit changes in rhythmic burst firing and increased excitability after spinal cord contusion injury [36], and that these activities are likely regulated by HCN-mediated Ih currents [37]. There are four HCN channel isoforms (HCN1–4) expressed in the CNS with distinct expression patterns [38,39]. The regulation of animal behaviors by HCN channels depends on channel subunits, subcellular localization, cell types, and brain regions. HCN2 channels have been reported to be widely expressed in the thalamus (including the VPL). Previous studies portray enhanced expressions of HCN2 channels in DRG neurons in mice with neuropathic and inflammatory pain [40,41]. Consistent with these studies, our findings reveal significant increases in HCN2 channel protein levels and in Ih currents of VPLGlu neurons under chronic pain states. Blockade of HCN2 in the VPL decreases the activity of the VPLGlu→S1HLGlu pathway and alleviates allodynia. These findings indicate that HCN2 channel-mediated neural circuit plasticity is a foundation for the development of chronic pain.
HCN2 channels are opened tonically at −65 mV, which leads to persistent inward and mixed Na+/K+ currents and contribute to generation of the tonic and burst firing of thalamic neurons [42,43]. In our study, we observed that inhibition of HCN2 channels reversed the elevation in tonic and burst firing of VPLGlu neurons caused membrane hyperpolarization. In addition, HCN2 channels are known to be regulated by the cAMP signaling [44]. It has been reported that the intracellular cAMP was increased in somatosensory neurons in an animal model of painful diabetes [45]. In the current study, we found cAMP levels are increased in the VPL of SNI and CFA model mice, and that application of the cAMP blocker, SQ22536, decreases Ih currents and lowers the pain threshold in these mice. These results suggest that the cAMP signaling contributes to the effects of HCN2 channels on chronic pain.
The pain hypersensitivity is inextricably linked to functional connections between the thalamus and the cortical regions involved in nociceptive processing [35]. fMRI studies showed that functional connectivity in the thalamocortical network was enhanced in pain chronicity in humans [46]. The precise structure of thalamocortical circuits and their functional changes in chronic pain are poorly understood, and it remains unclear as to how ion channels in the thalamus that regulate thalamic neuronal firing affect the activity of the thalamocortical circuit. Herein, we identified an excitatory VPLGlu→S1HLGlu thalamocortical neural circuit, the activity of which appears to be regulated by HCN2 channels. We also substantiated that downregulation of HCN2 channels can reverse the hyperactivity of the VPLGlu→S1HLGlu neural circuit and relieve allodynia in SNI 7D and CFA 3D mice. Our findings thus delineate an ion channel-regulated neural circuit involved in the development of chronic pain.
Numerous brain regions are activated under chronic-pain conditions—such as PO, parafascicular nucleus, the paraventricular nucleus of the hypothalamus, and the lateral habenula [47–49]. With regard to the source of the enhanced activity of the VPLGlu→S1HLGlu pathway in chronic-pain conditions, another theory entails the interaction between specific neurons within the different subnuclei of the thalamus or in other brain areas. Evidence from experimental animal studies revealed that optogenetically activated thalamic reticular nucleus (TRN) neurons projecting to the VPL reduced thermal hyperalgesia in chronic inflammatory pain in mice while reducing GABAergic transmission promoted pain [50]. Investigators have also recently shown that the optic stimulation of the NAc nucleus could alleviate the discharge of the VPL nucleus in the pain model of DRG neuropathic pain by reducing pain information traveling into the thalamus via the spinothalamic tract [51]. These results indicate that VPL neurons perform specific, essential roles for noxious-stimulation responses; the relationship between diverse brain regions and the VPL in various animal models of pain-sensing is a worthwhile investigative endeavor.
Different cortices receive projections from distinct subdivisions of the thalamus, which may perform various functions in the pathology of chronic pain [35]. In the current study, viral tracing showed that the VPLGlu neurons mainly provided projections to the S1, but not the ACC, PFC, or IC; and the allodynia could be reversed by inhibition of VPLGlu neuronal terminals in the S1HL. Although no projection from the VPL to ACC was observed in the current study, it should be noted that optical inhibition of ACCGlu neurons is demonstrated to reduce the mechanical pain threshold in CFA mice [52]. A previous study has shown that the ACC receives inputs from the S1 and the activation of S1Glu neuronal terminals in the ACC can increase the ACCGlu neuronal response to noxious stimuli [53]. Hence, suppression of S1-projecting VPLGlu neuronal activity could decrease the excitability of ACCGlu neurons, thus alleviating pain behaviors.
In summary, our study illustrates the functional role of HCN2 channels in the regulation of the VPLGlu→S1HLGlu circuit and provides novel insights into the neural circuit, cellular and molecular mechanisms underlying chronic pain. As the clinical analgesic drugs currently administered for chronic pain treatment remain unsatisfactory, our findings implicate HCN2 channels as potential therapeutic targets in the management of chronic pain.
MATERIALS AND METHODS
For detailed materials and methods, please see the Supplementary data. All data were available in this manuscript.
Animals
Male mice at 8 to 10 weeks of age were used in all experiments. All animal protocols were approved by the Animal Care and Use Committee of the University of Science and Technology of China (permit USTCACUC1901001).
Animal models
SNI and CFA protocols were used to construct mouse models of chronic pain.
Statistical analysis
Two-tailed Student's t-tests, one-way and two-way ANOVA with post hoc analyses were used to perform statistical comparisons. All data are presented as mean ± SEM.
Supplementary Material
Contributor Information
Jun-Ma Yu, Department of Anesthesiology, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei 230061, China.
Rui Hu, Department of Anesthesiology, The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei 230061, China.
Yu Mao, Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; Department of Biophysics and Neurobiology, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
Yingju Tai, Department of Biophysics and Neurobiology, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
Sen Qun, Stroke Center and Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
Zhi Zhang, Department of Biophysics and Neurobiology, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
Danyang Chen, Department of Biophysics and Neurobiology, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
Yan Jin, Stroke Center and Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.
FUNDING
This work was supported by the National Key Research and Development Program of China (2021ZD0203100), the National Natural Science Foundation of China (32025017, 32121002, 82171218, 82101300, 82101301), the CAS Project for Young Scientists in Basic Research (YSBR-013), the Youth Innovation Promotion Association CAS, the CAS Collaborative Innovation Program of Hefei Science Center (2021HSC-CIP013), the Fundamental Research Funds for the Central Universities (WK9100000030), the USTC Research Funds of the Double First-Class Initiative (YD9100002018), the Natural Science Foundation of Anhui Province (2208085J30, 2008085QC114), and the Innovative Research Team of High level Local Universities in Shanghai.
Author Contributions
Conceptualization, Z. Z., D. C., and Y. J.; methodology, J-M. Y., R. H., Y. M., and Y. T.; software, J-M. Y., R. H., Y. M., and Y. T.; investigation, J-M. Y., R. H., Y. M., Y. T., and Y. J.; formal analysis, J-M. Y., R. H., Y. M., and Y. T.; writing—original draft, J-M. Y., R. H., Y. M., and Y. J.; writing—review and editing, J-M. Y., R. H., Y. M., Z. Z., D. C., and Y. J.; funding acquisition, Y. M., Z. Z., D. C., and Y. J.; resources, R. H., Y. M., S. Q., and Y. T.; supervision, J-M. Y., Z. Z., D. C., and Y. J.
Conflict of interest statement
None declared.
References
- 1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet North Am Ed 2021; 397: 2082–97. 10.1016/S0140-6736(21)00393-7 [DOI] [PubMed] [Google Scholar]
- 3. Choi S, Hachisuka J, Brett MAet al. Parallel ascending spinal pathways for affective touch and pain. Nature 2020; 587: 258–63. 10.1038/s41586-020-2860-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Navratilova E, Porreca F. Reward and motivation in pain and pain relief. Nat Neurosci 2014; 17: 1304–12. 10.1038/nn.3811 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Wager TD, Rilling JK, Smith EEet al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303: 1162–7. 10.1126/science.1093065 [DOI] [PubMed] [Google Scholar]
- 6. Bliss TV, Collingridge GL, Kaang B-Ket al. Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Nat Rev Neurosci 2016; 17: 485–96. 10.1038/nrn.2016.68 [DOI] [PubMed] [Google Scholar]
- 7. Zhou H, Zhang Q, Martinez Eet al. Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex. Nat Commun 2018; 9: 3751. 10.1038/s41467-018-06295-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci 2013; 14: 502–11. 10.1038/nrn3516 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zhang MM, Geng AQ, Chen Ket al. Glutamatergic synapses from the insular cortex to the basolateral amygdala encode observational pain. Neuron 2022; 110: 1993–2008.e6. 10.1016/j.neuron.2022.03.030 [DOI] [PubMed] [Google Scholar]
- 10. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 1769–72. 10.1126/science.288.5472.1769 [DOI] [PubMed] [Google Scholar]
- 11. Kim JH, Greenspan JD, Coghill RCet al. Lesions limited to the human thalamic principal somatosensory nucleus (ventral caudal) are associated with loss of cold sensations and central pain. J Neurosci 2007; 27: 4995–5004. 10.1523/JNEUROSCI.0716-07.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Zhang ZL, Yu G, Liang XNet al. Selective downregulation of vesicular glutamate transporter2 in ventral posterolateral nucleus of thalamus attenuates neuropathic mechanical allodynia in mice. Eur J Pharmacol 2018; 828: 103–9. 10.1016/j.ejphar.2018.03.040 [DOI] [PubMed] [Google Scholar]
- 13. Kovanlikaya I, Heier L, Kaplitt M. Treatment of chronic pain: diffusion tensor imaging identification of the ventroposterolateral nucleus confirmed with successful deep brain stimulation. Stereotact Funct Neurosurg 2014; 92: 365–71. 10.1159/000366002 [DOI] [PubMed] [Google Scholar]
- 14. Henderson LA, Peck CC, Petersen ETet al. Chronic pain: lost inhibition? J Neurosci 2013; 33: 7574–82. 10.1523/JNEUROSCI.0174-13.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Tu Y, Fu Z, Mao Cet al. Distinct thalamocortical network dynamics are associated with the pathophysiology of chronic low back pain. Nat Commun 2020; 11: 3948. 10.1038/s41467-020-17788-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Cummiford CM, Nascimento TD, Foerster BRet al. Changes in resting state functional connectivity after repetitive transcranial direct current stimulation applied to motor cortex in fibromyalgia patients. Arthritis Res Ther 2016; 18: 40. 10.1186/s13075-016-0934-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Santoro B, Shah MM. Hyperpolarization-activated cyclic nucleotide-gated channels as drug targets for neurological disorders. Annu Rev Pharmacol Toxicol 2020; 60: 109–31. 10.1146/annurev-pharmtox-010919-023356 [DOI] [PubMed] [Google Scholar]
- 18. Wahl-Schott C, Fenske S, Biel M. HCN channels: new roles in sinoatrial node function. Curr Opin Pharmacol 2014; 15: 83–90. 10.1016/j.coph.2013.12.005 [DOI] [PubMed] [Google Scholar]
- 19. Tibbs GR, Posson DJ, Goldstein PA. Voltage-gated ion channels in the PNS: novel therapies for neuropathic pain? Trends Pharmacol Sci 2016; 37: 522–42. 10.1016/j.tips.2016.05.002 [DOI] [PubMed] [Google Scholar]
- 20. Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic- and antidepressant-like behaviors. Neuron 2012; 75: 503–16. 10.1016/j.neuron.2012.05.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Chen K, Aradi I, Thon Net al. Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability. Nat Med 2001; 7: 331–7. 10.1038/85480 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Nolan MF, Malleret G, Dudman JTet al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell 2004; 119: 719–32. [DOI] [PubMed] [Google Scholar]
- 23. Ding W, You Z, Shen Set al. Increased HCN channel activity in the gasserian ganglion contributes to trigeminal neuropathic pain. J Pain 2018; 19: 626–34. 10.1016/j.jpain.2018.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Emery EC, Young GT, Berrocoso EMet al. HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science 2011; 333: 1462–6. 10.1126/science.1206243 [DOI] [PubMed] [Google Scholar]
- 25. Forster LA, Jansen LR, Rubaharan Met al. Alterations in SUMOylation of the hyperpolarization-activated cyclic nucleotide-gated ion channel 2 during persistent inflammation. Eur J Pain 2020; 24: 1517–36. 10.1002/ejp.1606 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009; 10: 283–94. 10.1038/nrn2606 [DOI] [PubMed] [Google Scholar]
- 27. Kuner R, Kuner T. Cellular circuits in the brain and their modulation in acute and chronic pain. Physiol Rev 2021; 101: 213–58. 10.1152/physrev.00040.2019 [DOI] [PubMed] [Google Scholar]
- 28. Wan Y, Feng B, You Yet al. Microglial displacement of GABAergic synapses is a protective event during complex febrile seizures. Cell Rep 2020; 33: 108346. 10.1016/j.celrep.2020.108346 [DOI] [PubMed] [Google Scholar]
- 29. Park GH, Noh H, Shao Zet al. Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nat Neurosci 2020; 23: 1352–64. 10.1038/s41593-020-00724-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. An K, Zhao H, Miao Yet al. A circadian rhythm-gated subcortical pathway for nighttime-light-induced depressive-like behaviors in mice. Nat Neurosci 2020; 23: 869–80. 10.1038/s41593-020-0640-8 [DOI] [PubMed] [Google Scholar]
- 31. Sartiani L, Mannaioni G, Masi Aet al. The hyperpolarization-activated cyclic nucleotide-gated channels: from biophysics to pharmacology of a unique family of ion channels. Pharmacol Rev 2017; 69: 354–95. 10.1124/pr.117.014035 [DOI] [PubMed] [Google Scholar]
- 32. Tsantoulas C, Mooney ER, McNaughton PA. HCN2 ion channels: basic science opens up possibilities for therapeutic intervention in neuropathic pain. Biochem J 2016; 473: 2717–36. 10.1042/BCJ20160287 [DOI] [PubMed] [Google Scholar]
- 33. Cheng J, Umschweif G, Leung Jet al. HCN2 channels in cholinergic interneurons of nucleus accumbens shell regulate depressive behaviors. Neuron 2019; 101: 662–672. 10.1016/j.neuron.2018.12.018 [DOI] [PubMed] [Google Scholar]
- 34. Basbaum AI, Bautista DM, Scherrer Get al. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267–84. 10.1016/j.cell.2009.09.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev 2021; 101: 259–301. 10.1152/physrev.00045.2019 [DOI] [PubMed] [Google Scholar]
- 36. Hains BC, Saab CY, Waxman SG. Alterations in burst firing of thalamic VPL neurons and reversal by Na(v)1.3 antisense after spinal cord injury. J Neurophysiol 2006; 95: 3343–52. 10.1152/jn.01009.2005 [DOI] [PubMed] [Google Scholar]
- 37. Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 2003; 65: 453–80. 10.1146/annurev.physiol.65.092101.142734 [DOI] [PubMed] [Google Scholar]
- 38. Notomi T, Shigemoto R. Immunohistochemical localization of Ih channel subunits, HCN1–4, in the rat brain. J Comp Neurol 2004; 471: 241–76. 10.1002/cne.11039 [DOI] [PubMed] [Google Scholar]
- 39. Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov 2011; 10: 903–14. 10.1038/nrd3576 [DOI] [PubMed] [Google Scholar]
- 40. Jansen LR, Forster LA, Smith XLet al. Changes in peripheral HCN2 channels during persistent inflammation. Channels 2021; 15: 164–78. 10.1080/19336950.2020.1870086 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Huang H, Zhang Z, Huang D. Decreased HCN2 channel expression attenuates neuropathic pain by inhibiting pro-inflammatory reactions and NF-κB activation in mice. Int J Clin Exp Pathol 2019; 12: 154–63. [PMC free article] [PubMed] [Google Scholar]
- 42. Budde T, Caputi L, Kanyshkova Tet al. Impaired regulation of thalamic pacemaker channels through an imbalance of subunit expression in absence epilepsy. J Neurosci 2005; 25: 9871–82. 10.1523/JNEUROSCI.2590-05.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Endo T, Tarusawa E, Notomi Tet al. Dendritic Ih ensures high-fidelity dendritic spike responses of motion-sensitive neurons in rat superior colliculus. J Neurophysiol 2008; 99: 2066–76. 10.1152/jn.00556.2007 [DOI] [PubMed] [Google Scholar]
- 44. Ulens C, Siegelbaum SA. Regulation of hyperpolarization-activated HCN channels by cAMP through a gating switch in binding domain symmetry. Neuron 2003; 40: 959–70. 10.1016/S0896-6273(03)00753-0 [DOI] [PubMed] [Google Scholar]
- 45. Tsantoulas C, Lainez S, Wong Set al. Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy. Sci Transl Med 2017; 9: eaam6072. 10.1126/scitranslmed.aam6072 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Youssef AM, Azqueta-Gavaldon M, Silva KEet al. Shifting brain circuits in pain chronicity. Hum Brain Mapp 2019; 40: 4381–96. 10.1002/hbm.24709 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Zhu X, Tang HD, Dong WYet al. Distinct thalamocortical circuits underlie allodynia induced by tissue injury and by depression-like states. Nat Neurosci 2021; 24: 542–53. 10.1038/s41593-021-00811-x [DOI] [PubMed] [Google Scholar]
- 48. Deng J, Zhou H, Lin JKet al. The parabrachial nucleus directly channels spinal nociceptive signals to the intralaminar thalamic nuclei, but not the amygdala. Neuron 2020; 107: 909–23. 10.1016/j.neuron.2020.06.017 [DOI] [PubMed] [Google Scholar]
- 49. Zhou W, Jin Y, Meng Qet al. A neural circuit for comorbid depressive symptoms in chronic pain. Nat Neurosci 2019; 22: 1649–58. 10.1038/s41593-019-0468-2 [DOI] [PubMed] [Google Scholar]
- 50. Zhang C, Chen RX, Zhang Yet al. Reduced GABAergic transmission in the ventrobasal thalamus contributes to thermal hyperalgesia in chronic inflammatory pain. Sci Rep 2017; 7: 41439. 10.1038/srep41439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Elina KC, Moon HC, Kim Set al. Optical modulation on the nucleus accumbens core in the alleviation of neuropathic pain in chronic dorsal root ganglion compression rat model. Neuromodulation 2020; 23: 167–76. 10.1111/ner.13059 [DOI] [PubMed] [Google Scholar]
- 52. Kang SJ, Kwak C, Lee Jet al. Bidirectional modulation of hyperalgesia via the specific control of excitatory and inhibitory neuronal activity in the ACC. Mol Brain 2015; 8: 81. 10.1186/s13041-015-0170-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Singh A, Patel D, Li Aet al. Mapping cortical integration of sensory and affective pain pathways. Curr Biol 2020; 30: 1703–15. 10.1016/j.cub.2020.02.091 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.